Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a report released on Monday,Benzinga reports. They currently have a $65.00 price target on the stock.

GPCR has been the subject of a number of other research reports. Citigroup initiated coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a “buy” rating and a $60.00 price target for the company. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating for the company. HC Wainwright cut their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, May 12th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $89.00 price objective on shares of Structure Therapeutics in a research note on Monday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $76.17.

Structure Therapeutics Trading Up 1.7%

Shares of NASDAQ:GPCR opened at $22.10 on Monday. The company has a 50 day moving average of $23.32 and a 200 day moving average of $24.06. The stock has a market cap of $1.27 billion, a P/E ratio of -25.40 and a beta of -1.87. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $47.48.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors have recently made changes to their positions in GPCR. Deep Track Capital LP boosted its stake in shares of Structure Therapeutics by 129.4% in the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after purchasing an additional 1,579,492 shares in the last quarter. Vestal Point Capital LP raised its holdings in Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after buying an additional 575,000 shares during the last quarter. Boxer Capital Management LLC bought a new stake in Structure Therapeutics during the 4th quarter valued at $13,560,000. Marshall Wace LLP raised its holdings in Structure Therapeutics by 339.6% during the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company’s stock valued at $15,817,000 after buying an additional 450,531 shares during the last quarter. Finally, Foresite Capital Management VI LLC bought a new stake in Structure Therapeutics during the 4th quarter valued at $11,390,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.